| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
09-07-2016, 09:17 AM
|
#1 | ||
|
|||
|
Member
|
New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson's protein alpha-synuclein. Today the company announced its "boost" follow-up study -- funded with a $1.04 million grant from The Michael J. Fox Foundation -- showed that an additional dose is safe and can elicit antibodies against alpha-synuclein. AFFiRiS will present a poster on the study at the World Parkinson Congress in Portland, Oregon on Wednesday, September 21.
Parkinson's Disease | Vaccine for Parkinson's Reports Positive Results from Boost Study |
||
|
 Reply With Quote
|
| "Thanks for this!" says: | Betsy859 (09-12-2016), Debi Brooks (09-08-2016), eds195 (09-07-2016), hercules957 (09-07-2016), lab rat (09-08-2016), Nan Cyclist (09-07-2016), olsen (09-07-2016) |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| GDNF Trials explained--Thank you Parkinson's UK and Cure Parkinson's Trust | Parkinson's Disease | |||
| Possible cure for Parkinson's? | Parkinson's Disease | |||
| Finding a cure for Parkinson's | Parkinson's Disease | |||
The plot seems to thicken on the way to the Parkinson's cure!
Threaded Mode